NL-OMON40382撤回不适用
Direct validation of renal123I-MIBG scintigraphy in humans - DIVIDERE study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational invasive
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- age 18 to 85 years
- •- able to give informed consent
- •- scheduled for radical nephrectomy, nephron-sparing partial nephrectomy or nephroureterectomy (only scheduled on Tuesdays to Fridays)
排除标准
- •- not willing to be informed about unexpected findings during the study
- •- pregnancy
- •- donor nephrectomy
- •- nephrectomy scheduled on Mondays
研究者
相似试验
Unknown
3 期
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine TumorsMedullary Thyroid CarcinomaNeuroblastomaCarcinoid TumorsPheochromocytomaParagangliomaNCT01373736Vancouver Coastal Health
已完成
3 期
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaPheochromocytomaNeuroblastomaNCT00126412GE Healthcare251
招募中
4 期
MIBG scintigraphy and Strain Echocardiography in the early detection of late cardiovascular effects of (neo)adjuvant breast cancer treatment with docetaxel, doxorubicin and cyclophosphamide (TAC): a pilot studycardiac injurycardiotoxicity10082206NL-OMON34932Integraal Kankercentrum Oost150
已完成
不适用
Evaluation of 99mTc-DMSA static renal scintigraphy in acute period of first upper urinary tract infection.pper urinary tract infection (Acute pyelonephritis, Acute focal bacterial nephronia)JPRN-UMIN000008860Chiba Kaihin Municipal Hospital30
进行中（未招募）
1 期
A Phase I study of 131-I mIBG followed by Nivolumab and Dinutuximab beta Antibodies in children with relapsed/refractory Neuroblastoma.Relapsed or refractory high risk neuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-002221-11-DEniversity Hospital Southampton NHS Foundation Trust (UK)36